Feeding-Triggered Seizures in a Newborn with AP1S1-Related MEDNIK Syndrome: Expanding the Phenotype of a Hyper-Rare Disease
Related Experiment Video
Updated: Jan 13, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Anna Cavalli1, Francesca Peluso2, Daniele Frattini1
1Child Neurology and Psychiatry Unit, Arcispedale Santa Maria Nuova, AUSL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Insights
MEDNIK syndrome, a rare genetic disorder, can manifest early with severe enteropathy and feeding-related seizures. This case highlights a new AP1S1 variant and zinc acetate treatment, offering insights into this condition.
Area of Science:
- Genetics and Molecular Biology
- Pediatric Medicine
- Neurology
Background:
- MEDNIK syndrome is a severe, hyper-rare genetic disorder caused by biallelic variants in the AP1S1 gene.
- It affects intracellular trafficking and copper homeostasis, leading to high early lethality, primarily due to congenital enteropathy.
- Limited data exists on the clinical course and early neurological manifestations, such as epilepsy, in MEDNIK syndrome.
Abstract:
MEDNIK syndrome (Mental Retardation, Enteropathy, Deafness, Neuropathy, Ichthyosis and Keratodermia) is a severe hyper-rare condition resulting from the biallelic variants in the AP1S1 gene, implicated in intracellular trafficking and copper homeostasis. Only 18 affected individuals (seven AP1S1 pathogenic variants overall) have been reported to date, with a high early lethality due to life-threatening congenital enteropathy. Seven patients have been empirically treated with zinc. Due to the paucity of literature data, little is known about the clinical course of individuals affected by MEDNIK syndrome, and the possible early association with epilepsy needs to be investigated. We present the first case of Italian origin affected by MEDNIK syndrome carrying a new homozygous AP1S1 stop variant, presenting with congenital severe enteropathy and feeding-related seizures, thus representing an early, singular manifestation of the disease. We describe her clinical course and the zinc acetate therapeutic experience. We also reviewed the literature focusing on clinical manifestations (especially neurological), brain neuroimaging and the symptom evolution of patients with AP1S1-related MEDNIK syndrome and discuss possible future therapeutic attempts.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...

